"Promising Experimental Treatment Enables Liver Regeneration in Patients"
A biotech company, LyGenesis, has begun human trials for an experimental treatment that involves injecting a cocktail containing donated liver cells into patients with end-stage liver disease, aiming to transform a lymph node into a functional liver. If successful, this therapy could potentially allow one donated liver to treat many ESLD patients, addressing the current organ supply-demand imbalance. The treatment, which has shown promise in animal tests, could provide a lifeline for the thousands of people on the liver transplant waiting list by utilizing only a few cells from a liver to treat multiple patients.